| Autor: |
Moatasim Y; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt., Kutkat O; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt., Osman AM; Biochemistry Department, Faculty of Science, Cairo University, Cairo 12613, Egypt., Gomaa MR; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt., Okda F; Veterinary Research Institute, National Research Centre, Giza 12622, Egypt.; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA., El Sayes M; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt., Kamel MN; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt., Gaballah M; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt., Mostafa A; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt., El-Shesheny R; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt., Kayali G; Human Link, Dubai 115738, United Arab Emirates., Ali MA; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt., Kandeil A; Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza 12622, Egypt. |
| Abstrakt: |
Repurposing vitamins as antiviral supporting agents is a rapid approach used to control emerging viral infections. Although there is considerable evidence supporting the use of vitamin supplementation in viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the specific role of each vitamin in defending against coronaviruses remains unclear. Antiviral activities of available vitamins on the infectivity and replication of human coronaviruses, namely, SARS-CoV-2, Middle East respiratory syndrome coronavirus (MERS-CoV), and human coronavirus 229E (HCoV-229E), were investigated using in silico and in vitro studies. We identified potential broad-spectrum inhibitor effects of Hydroxocobalamin and Methylcobalamin against the three tested CoVs. Cyanocobalamin could selectively affect SARS-CoV-2 but not MERS-CoV and HCoV-229E. Methylcobalamin showed significantly higher inhibition values on SARS-CoV-2 compared with Hydroxocobalamin and Cyanocobalamin, while Hydroxocobalamin showed the highest potent antiviral activity against MERS-CoV and Cyanocobalamin against HCoV-229E. Furthermore, in silico studies were performed for these promising vitamins to investigate their interaction with SARS-CoV-2, MERS-CoV, and HCoV-229E viral-specific cell receptors (ACE2, DPP4, and hAPN protein, respectively) and viral proteins (S-RBD, 3CL pro, RdRp), suggesting that Hydroxocobalamin, Methylcobalamin, and Cyanocobalamin may have significant binding affinity to these proteins. These results show that Methylcobalamin may have potential benefits for coronavirus-infected patients. |
